![Dov, Multiple Sclerosis, Israel](/optim/dotcom/pages/images/partnering/partnering-focus-areas/neuroscience-partnerships/our-neuroscience-goals_20240223112519.jpg?size=xlarge)
Our Neuroscience Goals
We focus on modulating neuroinflammation, facilitating neuroprotection, repair, and remyelination in neurological diseases, and slowing down or halting neurodegeneration.
![Neurons sending pulsating electric impulses](/optim/dotcom/pages/images/partnering/partnering-focus-areas/neuroscience-partnerships/a-shared-commitment_20240223112519.jpg?size=large)
A Shared Commitment
We partner with companies that share our commitment and bring expertise in translational neuroscience and technologies.
Partnering Success Stories
![](/optim/dotcom/pages/images/partnering/partnering-focus-areas/partnering-focus-areas-logos/partnering-logo-denali_20240223112519.jpg?size=large)
Denali Therapeutics
We’re collaborating to develop RIPK1 inhibitors for potential treatments of neurological and inflammatory diseases, such as Alzheimer’s, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis.
![](/optim/dotcom/pages/images/partnering/partnering-focus-areas/partnering-focus-areas-logos/partnering-logo-ablbio_20240223112519.jpg?size=large)
ABL Bio
We’re collaborating to develop a potential first-in-class, bi-specific alpha-synuclein antibody for Parkinson’s disease. It’s designed as a “brain shuttle” that targets insulin-like growth factor 1 receptors.
Your Partnering Leads in Neuroscience
For more information, contact our Business development team
![Brian Bronk](/optim/dotcom/pages/images/partnering/partnering-brian-bronk_20240223112519.jpg?size=orig)
Brian Bronk
Global Head of Business Development, Neurology, Rare Diseases & Technology Platforms
![Guy Griebel](/optim/dotcom/pages/images/partnering/guy-griebel_20240223112519.png?size=orig)
Guy Griebel
Head of External Innovation, Rare and Neurological Disorders